Cagrilintide
Long-acting amylin analog studied for appetite suppression and satiety signaling. Most researched in combination with semaglutide (as CagriSema), where Phase 3 data showed greater weight reduction than either compound alone.
Studied Benefits
- Amylin/calcitonin receptor agonism
- Satiety-signaling research distinct from GLP-1 pathway
- Studied alongside semaglutide in Phase 3 combination trials
- Appetite-regulation research
Research Use Only
This compound is intended for laboratory and research purposes only. It is not approved for human consumption and is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional.
Independently Reviewed
We only list vendors that provide third-party, batch-specific COAs.
Peak Lab Peptides
Buy Direct from Peak Lab Peptides →Affiliate disclosure: links above are affiliate partnerships. We may earn a commission at no cost to you.
Related in Body Composition
Semaglutide (GLP-1)
GLP-1 receptor agonist widely studied for appetite regulation, blood sugar control, and body composition.
View product →
Tirzepatide
Dual GIP/GLP-1 receptor agonist studied for synergistic effects on insulin secretion, fat metabolism, and appetite suppression — showing a greater magnitude of weight loss than semaglutide in head-to-head trials.
View product →
Make this protocol yours
The Engine reads your biometrics and personalizes dosing, timing, and stacking — free at engine.auraprotocols.com.
Try the Engine →